Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at up to $18.5 billion, was met with unexpected market skepticism, leading to a significant drop in stock prices for both companies involved [2][4][7]. Group 1: Strategic Collaboration Details - CSPC Pharmaceutical Group announced a strategic partnership with AstraZeneca to co-develop innovative long-acting peptide drugs based on CSPC's drug delivery technology and AI discovery platform [3][4]. - The agreement includes a $1.2 billion upfront payment, up to $3.5 billion in research milestone payments, and $13.8 billion in sales milestone payments, along with a double-digit revenue share based on annual net sales [4][5]. - This deal surpasses the previous record of $11.4 billion set by Innovent Biologics and Takeda in 2025, marking a new high for outbound licensing in China's biopharmaceutical sector [4]. Group 2: Market Reaction and Concerns - Following the announcement, CSPC's stock fell by 9.82% to HKD 9.64 per share, while its closely related company, New Horizon Health, saw a drop of 15.72% [2][7]. - Analysts suggest that the market's negative reaction stems from concerns over the details of the deal and the companies' fundamentals, indicating that the perceived benefits may not align with the actual risks involved [7]. - The milestone payments are contingent on successful clinical trials and market performance, raising questions about the viability of CSPC's projects in a competitive landscape [7][8]. Group 3: Product and Competitive Landscape - The core asset in this collaboration is SYH2082, a long-acting weight management drug currently in Phase I clinical trials, targeting GLP-1R and GIPR receptors [8][9]. - The competitive landscape for GLP-1 drugs is intensifying, with major players like Eli Lilly and domestic companies rapidly advancing their own dual-target and multi-target drugs [9][10]. - CSPC's late entry into the clinical phase with SYH2082 presents challenges in efficacy differentiation and safety optimization, which will be critical for its future competitiveness [10]. Group 4: Financial Context and Implications - CSPC's decision to pursue this significant licensing deal comes at a time when its financial performance is under pressure, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [11]. - New Horizon Health stands to benefit from the upfront payment, which will help alleviate its cash flow issues as it anticipates a significant net loss in 2025 due to high R&D expenditures [12].

孟科含 Kehan Meng 聂照亿 Zhaoyi Nie kh.meng@htisec.com john.zy.nie@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康在创新多肽分子发现和长效递 送产品的开发领域开展全面战略合作。 ...

Core Insights - The innovative drug Enoglutide Injection (brand name Xianyida) developed by Hangzhou Xianweida Biotechnology Co., Ltd. has received approval from the National Medical Products Administration, marking a significant milestone for the company and the industry [1] - This drug is aimed at blood sugar control for adult patients with type 2 diabetes and is the first approved innovative drug in Zhejiang Province for 2026, providing a new treatment option for over 100 million diabetes patients globally [1] Company Overview - Xianweida was established in August 2017 and has focused on innovative weight management therapies for obesity and related diseases [1] - Enoglutide is the company's first approved product and represents a breakthrough as the world's first biased GLP-1 (glucagon-like peptide-1) hypoglycemic drug [1] - The biased GLP-1 developed by Xianweida offers a significant upgrade over traditional GLP-1 receptor agonists, achieving better clinical efficacy while maintaining blood sugar control [1] Product Pipeline and Market Position - In addition to type 2 diabetes, Xianweida is targeting indications for overweight/obesity with multiple products in the pipeline, including a submitted application for Enoglutide for obesity in China [2] - The company is developing several oral products and aims to become the "first stock in weight management" by submitting a prospectus to the Hong Kong Stock Exchange in September 2025 [2] - The GLP-1 sector is currently one of the hottest areas in the global biopharmaceutical field, attracting major pharmaceutical companies like Novo Nordisk, Eli Lilly, Pfizer, and AstraZeneca, as well as numerous innovative biotech firms in China [2] Industry Context - The successful approval of the new drug is seen as a significant milestone for Chinese pharmaceutical companies in the field of metabolic diseases [2] - Hangzhou has been promoting rapid development in the biopharmaceutical industry through policy support and ecosystem optimization, with 5 innovative drugs approved in 2025, accounting for 83% of the total in the province [2] - The Hangzhou Medical Port has seen 132 innovative drugs enter clinical trials, with 4 currently in the approval process [2]

1月30日，新诺威（300765）及其间接控股股东石药集团相继公告，宣布与全球生物制药巨头阿斯利康 (AstraZeneca)签署战略研发合作与授权协议，将在创新多肽分子发现和长效递送产品的开发领域开展全 面战略合作。 合作总金额 最高可达185亿美元 根据石药集团公告，在中国以外，阿斯利康将获得该集团"每月一次注射用体重管理产品组合"的全球独 家权利——包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临床)，以及 三个处于临床前阶段、具备不同作用机制的研发项目。 根据石药集团公告，阿斯利康将向石药集团支付12亿美元预付款。此外，石药集团有权获得最高35亿美 元的潜在研发里程碑付款和最高138亿美元的潜在销售里程碑付款，以及基于相关授权产品年净销售额 的最高达双位数比例的销售提成。若所有里程碑均达成，该合作总金额最高可达185亿美元。 针对此次合作，添翼数字经济智库高级研究员吴婉莹对记者表示，此次石药集团与阿斯利康创纪录的战 略合作，标志着其"创新+国际化"战略取得里程碑式突破，不仅以巨额合作金额强力验证了其AI药物发 现与缓释给药等前沿技术平台的全球竞争力，为正处于传统 ...

[Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment 孟科含 Kehan Meng 聂照亿 Zhaoyi Nie 3）双方还将依托该等平台就另外四个新增项目开展合作。 kh.meng@htisec.com john.zy.nie@htisec.com 交易对价 [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康 ...

Core Insights - The collaboration between CSPC Pharmaceutical Group and AstraZeneca has resulted in unexpected outcomes, particularly the large scale of the business development (BD) deal exceeding market expectations [1][2] - Despite the substantial financial terms of the agreement, including a $1.2 billion upfront payment and potential milestone payments totaling up to $18.5 billion, the market reacted negatively, with CSPC's stock price dropping significantly [2][3] Summary by Sections Business Development Deal - CSPC's agreement with AstraZeneca is one of the largest in the history of Chinese innovative pharmaceuticals, with a total potential deal value of $18.5 billion [2] - The deal includes a $1.2 billion upfront payment, which is the second-largest in overseas licensing transactions among Chinese pharmaceutical companies [2][3] - The potential milestone payments are subject to uncertainties related to research progress and market sales, making them less reliable [2] Market Reaction - Following the announcement, CSPC's stock price fell by 10.2%, with its A-share subsidiary also experiencing a decline of over 17% [2][3] - This negative market response contrasts sharply with previous instances where pre-announced BD deals led to significant stock price increases, indicating a shift in market sentiment towards BD announcements [3][6] Changing Market Dynamics - The previous effectiveness of BD announcements as a catalyst for stock price increases has diminished, as the pharmaceutical sector has transitioned from a "negative expectation" phase to a more normalized valuation [5][7] - The market has begun to anticipate BD news, leading to preemptive stock price adjustments that result in profit-taking once the announcements are made [6][7] Future Outlook - The long-term prospects for the pharmaceutical sector remain strong, driven by the inherent performance potential of innovative drug assets [9][10] - Continuous policy support and improving fundamentals for companies are expected to foster a favorable environment for growth, shifting focus back to performance and fundamentals rather than BD speculation [10]

Core Viewpoint - Newnow (300765) announced a change in its management, appointing Dai Long as the new General Manager while he also holds the positions of Board Secretary and Securities Affairs Representative [1][4] Management Changes - Dai Long, born in June 1992, has a background in finance and has been with Newnow since December 2016, serving in various roles including Financial Manager and Board Secretary [4] - Despite being appointed to a key position, Dai Long does not hold any shares in Newnow and has no connections with major shareholders or other executives [4] - Dai Long's total pre-tax compensation for 2024 is reported at 223,200 yuan, a decrease of 121,100 yuan from 2023 [4][6] Executive Compensation - Other executives at Newnow also experienced significant salary reductions in 2024, with Vice General Manager Liu Gang's compensation dropping to 188,800 yuan, a decline of 18.89% year-on-year [7] - The collective salary cuts among executives are linked to the company's poor performance [7] Financial Performance - In 2024, Newnow reported revenues of 1.981 billion yuan, a year-on-year decrease of 21.98%, and a net profit attributable to shareholders of 53.7263 million yuan, down 87.63% [7] - The company anticipates further losses in 2025, projecting a net profit attributable to shareholders between -255 million yuan and -170 million yuan [7] Business Overview - Newnow, a core subsidiary of CSPC Pharmaceutical Group, was established in 1989 and went public in 2019 [7] - It is the largest production base for chemical synthetic xanthine products globally, with key products including caffeine and theobromine [7] - The company has developed a dual-driven business model focusing on traditional functional foods and innovative biopharmaceuticals [8] Strategic Developments - Newnow's subsidiary, Jushi Biotech, signed a strategic cooperation agreement with AstraZeneca for eight innovative long-acting peptide drug projects, with AstraZeneca agreeing to pay a $1.2 billion upfront fee and up to $17.3 billion in milestone payments [8] - Newnow plans to list on the Hong Kong Stock Exchange to expand financing channels for innovative drug research and development [8] - The company increased its stake in Jushi Biotech to 80% by acquiring 29% of its shares for 1.1 billion yuan [8] Market Performance - As of January 30, Newnow's stock price closed at 38.87 yuan per share, reflecting a decline of 15.72%, with a total market capitalization of 54.6 billion yuan [9]

Group 1: Market Overview - The Hong Kong stock market saw a net inflow of 32.22 billion HKD from northbound trading, with 20.39 billion HKD from Shanghai and 11.83 billion HKD from Shenzhen [1] - The most bought stocks included CSPC Pharmaceutical Group (01093), Xiaomi Group-W (01810), and the Tracker Fund of Hong Kong (02800) [1] Group 2: Notable Stock Transactions - CSPC Pharmaceutical Group (01093) received a net inflow of 9.36 billion HKD, following a strategic cooperation agreement with AstraZeneca for the development of innovative long-acting peptide drugs, potentially worth up to 18.5 billion USD [4] - The Tracker Fund of Hong Kong (02800) saw a net inflow of 5.89 billion HKD, with positive market sentiment driven by earnings recovery, improved liquidity, low valuations, and policy support [5] - Alibaba Group-W (09988) had a net inflow of 3.29 billion HKD, as it launched a high-end AI chip, enhancing its position in the AI technology sector [5] - Longi Green Energy Technology (06869) experienced a net inflow of 2.41 billion HKD, driven by strong demand for AI infrastructure and optical communication upgrades [5] Group 3: Stocks with Significant Net Outflows - Shandong Gold (01787) and Zijin Mining (02899) faced net outflows of 2.06 billion HKD and 6.35 billion HKD respectively, amid significant volatility in the precious metals market [7] - Semiconductor manufacturer SMIC (00981) saw a net outflow of 545.8 million HKD, with limited impact expected from the approval of H200 chips for the domestic market [7] - Xiaomi Group-W (01810) had a net inflow of 9.14 billion HKD, while China Mobile (00941) and CNOOC (00883) faced net outflows of 5.41 billion HKD and 5.25 billion HKD respectively [7]

不过，这一消息发布后，石药集团1月30日股价大跌，收跌10.2%，收盘价报9.6港元/股。旗下A股公司 新诺威收跌15.72%，收盘价为38.87元/股。 北京商报讯（记者 丁宁）1月30日，石药集团（01093.HK）发布公告称，已与阿斯利康签订战略研发合 作与授权协议，以利用石药集团专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽 药物。 公告显示，本次合作潜在总金额高达185亿美元，其中石药集团将获得12亿美元预付款，还将有权获得 最高35亿美元的潜在研发里程碑付款和最高138亿美元的潜在销售里程碑付款，以及基于相关授权产品 年净销售额的最高双位数比例销售提成。 ...

Core Viewpoint - The collaboration between Stone Pharmaceutical Group and AstraZeneca is a significant strategic partnership with a potential total deal value of up to $18.5 billion, highlighting the importance of innovative drug development and technology platforms in the pharmaceutical industry [1][2]. Group 1: Financial Aspects - The initial payment of $1.2 billion is the second-largest upfront payment in recent collaborations, following a $1.25 billion payment from a partnership between Three Life Pharmaceuticals and Pfizer in 2025 [2]. - The deal includes potential milestone payments of up to $3.5 billion for research and up to $13.8 billion for sales, along with a sales commission based on net sales of authorized products [1]. Group 2: Technological and Developmental Focus - The collaboration is centered around Stone Pharmaceutical Group's proprietary sustained-release drug delivery technology platform and AI-driven peptide drug discovery platform, indicating AstraZeneca's interest in the underlying technological capabilities [2]. - The sustained-release technology allows for monthly or longer dosing intervals for peptide drugs, enhancing patient compliance for long-term treatments [2]. - Stone Pharmaceutical Group will collaborate with AstraZeneca on the discovery of innovative peptide molecules and the development of long-acting delivery products, including a weight management product and several other projects in various stages of development [2][3]. Group 3: Historical Context and Market Position - This is not the first collaboration between Stone Pharmaceutical Group and AstraZeneca; the total deal value from their three collaborations has exceeded $25 billion [3]. - AstraZeneca has shown a strong commitment to the Chinese market, ranking first among foreign pharmaceutical companies in sales and actively engaging in patent licensing transactions [3]. - Stone Pharmaceutical Group, established in 1994, is transitioning from generic to innovative drug development, facing challenges with its key products as core patents expire [3][4]. Group 4: R&D Investment and Industry Trends - Stone Pharmaceutical Group has steadily increased its R&D spending from 2 billion yuan in 2019 to 5.19 billion yuan in 2024, reflecting its focus on innovative drug development [4]. - The company has eight innovative technology platforms and aims to launch a billion-yuan peak product annually from these platforms [4]. - The trend in the industry shows a surge in business development transactions, with over 150 deals and a total value exceeding $130 billion in 2025, indicating a robust market for innovative drug collaborations [4].